Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2017 / Cilt: 57 - Sayı: 1

PREDICTIVE VALUE OF GLASGOW PROG- NOSTIC SCORE ON TRANSRECTAL PROSTATE BIOPSY RESULTS

GLASGOW PROGNOSTİK SKORUNUN TRANSREKTAL PROSTAT BİYOPSİSİ SONUÇLARINI ÖNGÖRMEDEKİ YERİ

Pages
28–34
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean albumin level of the chronic prostatitis (CP) group was statistically significantly higher relative to the PCa group (p:0.005; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: We aimed to determine predictive value of an inflammation-based, minimally invasive prognostic marker of Glasgow prognostic score (GPS) in the diagnosis of prostate cancer (PCa) before performing prostate needle biopsy so as to decrease possible complications of prostate needle biopsy and increase its prostate cancer-specificity.Material and Methods: Among a total of 160 patients whose prostate specific antigen (PSA) levels were between 4-10 mg/dl without any suspicion of malignancy on digital rectal examination (DRE) who also underwent prostate needle biopsy. 30 patients whose histopathology results were reported as prostatic adenocarcinoma and 30 randomly selected patients with histologically evidenced chronic prostatitis were included in the study.
📊
Key Findings & Data:Before the procedure, serum PSA, C-reactive protein (CRP) and albumin levels, prostate volume, international prostate symptom score (IPSS) and presence of other comorbidities were reported.Results: Sixty patients aged 56-75 years (mean: 66.05±5.48 years) were included in the study.
💡
Conclusion & Impact:Mean albumin level of the chronic prostatitis (CP) group was statistically significantly higher relative to the PCa group (p:0.005; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: We aimed to determine predictive value of an inflammation-based, minimally invasive prognostic marker of Glasgow prognostic score (GPS) in the diagnosis of prostate cancer (PCa) before performing prostate needle biopsy so as to decrease possible complications of prostate needle biopsy and increase its prostate cancer-specificity.Material and Methods: Among a total of 160 patients whose prostate specific antigen (PSA) levels were between 4-10 mg/dl without any suspicion of malignancy on digital rectal examination (DRE) who also underwent prostate needle biopsy. 30 patients whose histopathology results were reported as prostatic adenocarcinoma and 30 randomly selected patients with histologically evidenced chronic prostatitis were included in the study. Before the procedure, serum PSA, C-reactive protein (CRP) and albumin levels, prostate volume, international prostate symptom score (IPSS) and presence of other comorbidities were reported.Results: Sixty patients aged 56-75 years (mean: 66.05±5.48 years) were included in the study. Mean ages of the cases, serum PSA and CRP levels were not statistically significantly different between groups (p>0.05). Mean albumin level of the chronic prostatitis (CP) group was statistically significantly higher relative to the PCa group (p:0.005; p

Özet

Amaç: Çalışmamızda, inflamasyon tabanlı ve minimal invaziv prognostik bir gösterge olan Glasgow prognostik skoru (GPS)' nun, prostat iğne biyopsisi öncesi prostat kanserini öngörebilme değerini saptamayı ve bu sayede prostat iğne biyopsisinin olası komplikasyonlarını azaltıp kansere spesifikliğini arttırabilmeyi amaçladık.Gereç ve Yöntemler: Prostat spesifik antijen (PSA) düzeyi 4-10 mg/dl arasında olan, rektal tuşede malignite şüphesi olmayan, prostat iğne biyopsisi yapılan toplamda 160 hasta içerisinden patoloji sonucu prostat adenokarsinomu gelen 30 hasta ve geri kalanlar içerisinden patoloji sonucu kronik prostatit olarak raporlanan hastalardan rastgele seçilen 30 hasta çalışmaya dahil edildi. Hastaların işlem öncesi serum PSA, C-reaktif protein (CRP), albümin düzeyi, prostat hacmi, vücut kitle indeksi (VKİ), uluslararası prostat semptom skorları (IPSS) ve diğer komorbiditelerin varlığı (diyabet, hipertansiyon, koroner arter hastalığı) belirlenip raporlandı.Bulgular: Çalışmaya dahil edilen 60 hastanın yaşları 56 ile 75 yıl arasında değişmekte olup, ortalaması 66.05±5.48 yıldır. Gruplara göre olguların yaş ortalamaları, serum PSA ve CRP düzeyleri arasında istatistiksel olarak anlamlı bir farklılık bulunmadı (p>0.05). Kronik prostatit (KP) grubunun serum albümin düzeyi ortalaması, prostat kanseri (PK) grubundan istatistiksel olarak anlamlı düzeyde yüksekti (p:0.005; p

🔖

Cite This Article

ŞAHİN, A., ÜRKMEZ, A., YILDIRIM, Ç., AKAN, S., YÜKSEL, Ö. H. (2022). PREDICTIVE VALUE OF GLASGOW PROG- NOSTIC SCORE ON TRANSRECTAL PROSTATE BIOPSY RESULTS. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 57 - Sayı: 1, 28–34. https://ajindex.com/articles/535230

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21:1232-7
  2. Liu ZQ, Chu L, Fang J-M, Zhang X, Zhao HX, Chen YJ, et al. Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2014; 16:467-71
  3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature.2008; 454:436-44
  4. Moore MM, Chua W, Charles KA. Inflammation and cancer: Causes and consequences. Clin Pharmacol Ther. 2010; 87: 504-8
  5. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol. 2013; 20:161-71
  6. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39:534-40
  7. Shafique K, Proctor MJ, McMillan DC, Leung H, Smith K, Sloan B, et al. The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer. 2013; 13: 292
  8. Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010; 13:71-7
  9. Lecornet E, Ahmed HU, Hu Y, Moore CM, Nevoux P, Barratt D, et al. The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol. 2012; 188:974- 80
  10. The European Association of Urology Nurses. Evidence-based Guidelines for Best Practice in Health Care Transrectal Ultrasound Guided Biopsy of the Prostate. 2011
  11. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010; 7;103:870-6
  12. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454: 436-44
  13. Bardan R, Dumache R, Dema A, Cumpanas A, Bucuras V. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem. 2014; 47:909-15. 14. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW. Circulating levels of coagulation and inflammation markers and cancer risks: I